Silk fibroin-based embolic agent for transhepatic artery embolization with multiple therapeutic potentials.
Biomedical behaviors
Clearance
Drug loading
Embolic agents
Enzymatic degradation
Iodination
Liver cancer
Multiple therapeutic potentials
Silk fibroin
Transhepatic artery embolization
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
19 Aug 2023
19 Aug 2023
Historique:
received:
20
02
2023
accepted:
29
07
2023
medline:
21
8
2023
pubmed:
20
8
2023
entrez:
19
8
2023
Statut:
epublish
Résumé
The excellent physicochemical and biomedical properties make silk fibroin (SF) suitable for the development of biomedical materials. In this research, the silk fibroin microspheres (SFMS) were customized in two size ranges, and then carried gold nanoparticles or doxorubicin to evaluate the performance of drug loading and releasing. Embolization efficiency was evaluated in rat caudal artery and rabbit auricular artery, and the in vivo distribution of iodinated SFMS ( SFMS were of smooth surface and regular shape with pervasive pores on the surface and inside the microspheres, and of suitable size range for TAE. Drug-loading functionalized SFMS with chemotherapy or radio-sensitization, and the enhanced therapeutic effects were proved in treating HUH-7 cells as lasting doxorubicin release or more lethal radiation. For artery embolization, SFMS effectively blocked the blood supply; when The feasibility of SFMS as degradable TARE agent for liver cancer was primarily proved as providing multiple therapeutic potentials.
Sections du résumé
BACKGROUND
BACKGROUND
The excellent physicochemical and biomedical properties make silk fibroin (SF) suitable for the development of biomedical materials. In this research, the silk fibroin microspheres (SFMS) were customized in two size ranges, and then carried gold nanoparticles or doxorubicin to evaluate the performance of drug loading and releasing. Embolization efficiency was evaluated in rat caudal artery and rabbit auricular artery, and the in vivo distribution of iodinated SFMS (
RESULTS
RESULTS
SFMS were of smooth surface and regular shape with pervasive pores on the surface and inside the microspheres, and of suitable size range for TAE. Drug-loading functionalized SFMS with chemotherapy or radio-sensitization, and the enhanced therapeutic effects were proved in treating HUH-7 cells as lasting doxorubicin release or more lethal radiation. For artery embolization, SFMS effectively blocked the blood supply; when
CONCLUSION
CONCLUSIONS
The feasibility of SFMS as degradable TARE agent for liver cancer was primarily proved as providing multiple therapeutic potentials.
Identifiants
pubmed: 37598140
doi: 10.1186/s12951-023-02032-9
pii: 10.1186/s12951-023-02032-9
pmc: PMC10439629
doi:
Substances chimiques
Iodine-131
0
Fibroins
9007-76-5
Gold
7440-57-5
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
278Subventions
Organisme : National Natural Science Foundation of China
ID : 81871390
Organisme : the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital) "Guhai Plan in the 14th Five-Year Plan period"
ID : GH145-22
Organisme : "Discipline Construction Climbing 234 Plan" of Shanghai Changhai Hospital of Naval Medical University
ID : 2020YPT002
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Eur J Pharm Sci. 2020 Oct 1;153:105496
pubmed: 32736094
Mater Sci Eng C Mater Biol Appl. 2019 Sep;102:820-828
pubmed: 31147054
Colloids Surf B Biointerfaces. 2021 Mar;199:111557
pubmed: 33434880
ACS Nano. 2020 May 26;14(5):5686-5699
pubmed: 32320228
J Mater Sci Mater Med. 2015 Jun;26(6):198
pubmed: 26105830
Science. 2010 Jul 30;329(5991):528-31
pubmed: 20671180
Adv Drug Deliv Rev. 2020 Jan 1;153:28-53
pubmed: 31678360
Expert Opin Drug Deliv. 2013 May;10(5):679-90
pubmed: 23406440
Health Phys. 2003 Sep;85(3):294-310
pubmed: 12938720
Biomaterials. 2022 May;284:121512
pubmed: 35405577
ACS Sustain Chem Eng. 2018 Sep 4;6(9):11704-11715
pubmed: 30881771
Adv Healthc Mater. 2018 Aug;7(16):e1800375
pubmed: 29809314
Nanoscale. 2015 Jan 14;7(2):625-36
pubmed: 25423473
Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):231-7
pubmed: 24030669
Colloids Surf B Biointerfaces. 2015 Jul 1;131:122-8
pubmed: 25982316
Semin Oncol. 2010 Apr;37(2):89-93
pubmed: 20494700
Adv Drug Deliv Rev. 2013 Apr;65(4):457-70
pubmed: 23137786
Mater Sci Eng C Mater Biol Appl. 2016 Jun;63:644-9
pubmed: 27040260
Hepatology. 2013 Dec;58(6):2188-97
pubmed: 23512791
Int J Nanomedicine. 2020 Jun 11;15:4091-4104
pubmed: 32606666
J Mater Chem. 2009 Jun 23;19(36):6443-6450
pubmed: 20161439
J Hazard Mater. 2020 Dec 5;400:122985
pubmed: 32580092
Adv Mater. 2019 Aug;31(33):e1901071
pubmed: 31168915
Front Immunol. 2020 Oct 30;11:590285
pubmed: 33193424
Biotechnol Appl Biochem. 2015 Jul-Aug;62(4):441-50
pubmed: 25196187
Radiology. 2022 Apr;303(1):215-225
pubmed: 35014906
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Acta Biomater. 2013 Jun;9(6):6823-33
pubmed: 23419554
Adv Funct Mater. 2013 Feb 18;23(7):854-861
pubmed: 23483738
Biomolecules. 2020 Dec 29;11(1):
pubmed: 33383963
Nanoscale Res Lett. 2015 Dec;10(1):367
pubmed: 26383542
Appl Radiat Isot. 2015 May;99:117-21
pubmed: 25748057
J Vasc Interv Radiol. 2014 Feb;25(2):240-7
pubmed: 24291001